ATE399539T1 - Histondeacetylase-inhibitor enthaltende formulierung zur zweiphasigen freisetzung - Google Patents

Histondeacetylase-inhibitor enthaltende formulierung zur zweiphasigen freisetzung

Info

Publication number
ATE399539T1
ATE399539T1 AT04010333T AT04010333T ATE399539T1 AT E399539 T1 ATE399539 T1 AT E399539T1 AT 04010333 T AT04010333 T AT 04010333T AT 04010333 T AT04010333 T AT 04010333T AT E399539 T1 ATE399539 T1 AT E399539T1
Authority
AT
Austria
Prior art keywords
profile
galenics
formulation
induction
hyperacetylation
Prior art date
Application number
AT04010333T
Other languages
English (en)
Inventor
Hanshermann Franke
Peter Lennartz
Alexander Maurer
Bernd Hentsch
Sascha Hoevelmann
Elke Martin
Original Assignee
Topotarget Germany Ag
Desitin Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topotarget Germany Ag, Desitin Arzneimittel Gmbh filed Critical Topotarget Germany Ag
Application granted granted Critical
Publication of ATE399539T1 publication Critical patent/ATE399539T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
AT04010333T 2004-04-30 2004-04-30 Histondeacetylase-inhibitor enthaltende formulierung zur zweiphasigen freisetzung ATE399539T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04010333A EP1591109B1 (de) 2004-04-30 2004-04-30 Histondeacetylase-Inhibitor enthaltende Formulierung zur zweiphasigen Freisetzung

Publications (1)

Publication Number Publication Date
ATE399539T1 true ATE399539T1 (de) 2008-07-15

Family

ID=34924816

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04010333T ATE399539T1 (de) 2004-04-30 2004-04-30 Histondeacetylase-inhibitor enthaltende formulierung zur zweiphasigen freisetzung

Country Status (19)

Country Link
US (1) US20070232528A1 (de)
EP (1) EP1591109B1 (de)
JP (1) JP4789927B2 (de)
CN (1) CN1980647B (de)
AT (1) ATE399539T1 (de)
AU (1) AU2005237251B2 (de)
BR (1) BRPI0509340A (de)
CA (1) CA2564877A1 (de)
CY (1) CY1108301T1 (de)
DE (1) DE602004014723D1 (de)
DK (1) DK1591109T3 (de)
ES (1) ES2308065T3 (de)
MX (1) MXPA06012568A (de)
NZ (1) NZ550879A (de)
PL (1) PL1591109T3 (de)
PT (1) PT1591109E (de)
SI (1) SI1591109T1 (de)
WO (1) WO2005105055A1 (de)
ZA (1) ZA200608714B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040883A2 (en) 1998-02-11 1999-08-19 Faller Douglas V Compositions and methods for the treatment of cystic fibrosis
CA2596210C (en) 2005-02-03 2014-07-08 Topotarget Uk Limited Combination therapies using hdac inhibitors
US8835501B2 (en) * 2005-05-13 2014-09-16 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
KR20080035683A (ko) * 2005-08-10 2008-04-23 노파르티스 아게 데아세틸라제 억제제의 사용 방법
WO2007054719A2 (en) 2005-11-10 2007-05-18 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
AU2005339587B2 (en) * 2005-11-16 2011-11-03 Universidad Nacional Autonoma De Mexico Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer
US20070207950A1 (en) * 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
DE102006006532B4 (de) 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
EP1839656A1 (de) * 2006-03-31 2007-10-03 TopoTarget Germany AG Verwendung von Valproicsäure zur topischen Verhandung von mild bis mässig Akne Vulgaris
WO2007145704A2 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
CA2661024A1 (en) * 2006-08-28 2008-03-06 The Regents Of The University Of California Small molecule potentiator of hormonal therapy for breast cancer
US8088951B2 (en) * 2006-11-30 2012-01-03 Massachusetts Institute Of Technology Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
CN101626763A (zh) * 2006-12-06 2010-01-13 北海道公立大学法人札幌医科大学 使用组蛋白脱乙酰酶（hdac）抑制物的细胞免疫增强
SI2099442T1 (sl) * 2006-12-26 2015-03-31 Pharmacyclics, Inc. Postopek uporabe inhibitorjev histon deacetilaze in spremljanje biomarkerjev v kombiniranjem zdravljenju
AU2007342028B2 (en) 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
CA2574531C (en) * 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
WO2008090534A1 (en) * 2007-01-26 2008-07-31 Berand Limited Methods and compositions for inhibition of excessive weight gain, reduction of inappropriate eating behaviours and inhibition of binge eating for the treatment of obesity
EP2170311A4 (de) * 2007-05-16 2011-10-19 Avalon Pharmaceuticals Verbindungen und verfharen zur behandlung oder prävention von autoimmunkrankheiten
WO2009040517A2 (en) * 2007-09-25 2009-04-02 Topotarget Uk Limited Methods of synthesis of certain hydroxamic acid compounds
EP2262493B1 (de) * 2008-03-07 2015-02-25 Topotarget A/S Behandlungsverfahren mit längerer kontinuierlicher infusion von belinostat
DE102008047515A1 (de) * 2008-09-12 2010-03-25 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung einer demyelinisierenden Erkrankung
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
WO2011038110A2 (en) * 2009-09-23 2011-03-31 The General Hospital Corporation Methods of treating metabolic disease
US20110086869A1 (en) * 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
CA2779497A1 (en) 2009-10-30 2011-05-05 Massachusetts Institute Of Technology The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders
WO2011063164A2 (en) * 2009-11-18 2011-05-26 Steady Sleep Rx Co., Inc. Sustained release cannabinoid medicaments
CN102802412A (zh) * 2009-12-08 2012-11-28 海玛奎斯特医药公司 用于治疗红细胞病症的方法及低剂量方案
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
NZ605526A (en) 2010-07-12 2015-04-24 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US9018176B2 (en) * 2010-12-02 2015-04-28 Susan Perrine Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders
DK2683371T3 (da) 2011-03-09 2021-01-18 Cereno Scient Ab Forbindelser og fremgangsmåder til forbedring af forringet endogen fibrinolyse ved anvendelse af histondeacetylasehæmmere
AU2011376953B2 (en) 2011-09-13 2017-08-24 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
WO2013039956A2 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating mood disorders
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
FR3025105B1 (fr) * 2014-09-02 2018-03-02 Centre Hospitalier Universitaire Pontchaillou Utilisation de l'acide valproique ou de ses derives dans le traitement des insuffisances en hepcidine et de leurs consequences
EP3445343B1 (de) * 2016-04-21 2026-02-25 Valcuria AB Zusammensetzung und verfahren zur vorbehandlung von krebs
MX2018013410A (es) * 2016-05-03 2019-06-06 Spectrix Therapeutics Llc Composiciones y metodos para proporcionar la hormona tiroidea o analogos de la misma.
CA3073866A1 (en) 2017-08-29 2019-03-07 Solural Pharma ApS Composition comprising suplatast tosilate
CN109705057B (zh) * 2017-10-25 2023-05-30 成都先导药物开发股份有限公司 组蛋白去乙酰化酶抑制剂及其制备方法与用途
CN108992442A (zh) * 2018-07-12 2018-12-14 上海交通大学医学院附属瑞金医院 Ms-275在制备促进胰岛素分泌药物中的用途
CN110882250B (zh) * 2018-09-07 2022-09-13 上海市生物医药技术研究院 Scriptaid在制备治疗弱精症药物和试剂及器械器皿中的应用
JP7541319B2 (ja) * 2019-04-18 2024-08-28 共和薬品工業株式会社 吸湿性成分を含むコーティング錠
CA3142142A1 (en) 2019-05-31 2020-12-03 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors
CN110652506A (zh) * 2019-11-09 2020-01-07 福建医科大学附属第一医院 三醋酸甘油酯在制备预防和治疗抑郁症药物中的用途
EP4081651B1 (de) * 2019-12-26 2026-02-25 Agency For Science, Technology And Research Belinostat erhöht die expression von mir-335 und seine verwendung bei der behandlung der atopischen dermatitis
CN111358777A (zh) * 2020-02-24 2020-07-03 军事科学院军事医学研究院环境医学与作业医学研究所 一种提高外周血单个核细胞线粒体功能的方法和应用
LT6874B (lt) * 2020-04-17 2021-12-10 Lietuvos sveikatos mokslų universitetas Valpro rūgšties ir dichloroacetato druskų derinio taikymas vėžio gydymui
US12553049B2 (en) 2020-06-30 2026-02-17 Korea University Research And Business Foundation Pharmaceutical composition containing SIRT7 inhibitor for preventing or treating allergic diseases
CN112998101A (zh) * 2021-04-20 2021-06-22 上海舒泽生物科技研究所 一种人体衰老kat7基因的抑制剂固体饮料及其制备方法
CN114306259B (zh) * 2021-11-18 2023-06-06 江苏宇锐医药科技有限公司 一种丙戊酸钠双层缓释片及其制备方法
CN115094142B (zh) * 2022-07-19 2024-05-28 中国医学科学院肿瘤医院 用于诊断肺肠型腺癌的甲基化标志物
CN117050855A (zh) * 2023-08-11 2023-11-14 慕恩（广州）生物科技有限公司 用于具有HDACi活性的菌株的筛选方法和装置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK152744C (da) * 1982-08-13 1988-10-31 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat
IT1215726B (it) * 1988-01-18 1990-02-22 Alfa Wassermann Spa Formulazioni galeniche a cessione programmata.
IL96311A (en) * 1989-12-01 1995-05-26 Abbott Lab Medications with delayed release
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
BR0007360A (pt) * 1999-12-23 2001-08-14 Johnson & Johnson Composição de liberação controlada
EP1170008A1 (de) * 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproinsäure und dessen Derivate als Inhibitoren der Histone deacetylase
JP4632166B2 (ja) * 2001-01-31 2011-02-16 日本ポリウレタン工業株式会社 リグノセルロース系熱圧成形体用接着剤組成物、及びそれを用いた熱圧成形体の製造方法

Also Published As

Publication number Publication date
AU2005237251B2 (en) 2010-11-04
EP1591109B1 (de) 2008-07-02
JP4789927B2 (ja) 2011-10-12
ES2308065T3 (es) 2008-12-01
CN1980647A (zh) 2007-06-13
CA2564877A1 (en) 2005-11-10
EP1591109A1 (de) 2005-11-02
ZA200608714B (en) 2008-07-30
CY1108301T1 (el) 2014-02-12
BRPI0509340A (pt) 2007-09-18
WO2005105055A1 (en) 2005-11-10
SI1591109T1 (sl) 2008-10-31
DK1591109T3 (da) 2008-10-06
JP2007535518A (ja) 2007-12-06
US20070232528A1 (en) 2007-10-04
AU2005237251A1 (en) 2005-11-10
NZ550879A (en) 2010-05-28
CN1980647B (zh) 2010-08-18
PT1591109E (pt) 2008-09-05
DE602004014723D1 (de) 2008-08-14
MXPA06012568A (es) 2007-04-30
PL1591109T3 (pl) 2008-11-28

Similar Documents

Publication Publication Date Title
ATE399539T1 (de) Histondeacetylase-inhibitor enthaltende formulierung zur zweiphasigen freisetzung
PH12015500832A1 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
DK1692097T3 (da) Tricykliske hydroxamat- og benzamidderivater, sammensætninger og fremgangsmåder
PH12021552194A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
PH12012501492B1 (en) Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
PH12020552228A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
ATE463490T1 (de) Histondeacetylase-hemmer
MA32539B1 (fr) Traitement du diabète chez des patients pour lesquels une thérapie par la metformine n'est pas appropriée
EA201291099A1 (ru) Новые иммуномодуляторные и противовоспалительные соединения
WO2009093119A3 (en) Use of serine protease inhibitors in the treatment of skin diseases
MXPA05011286A (es) Derivados de acetileno como inhibidores de histona deacetilasa.
DK1846424T3 (da) Proteasom-inhibitorer og fremgangsmåder til anvendelse deraf
EA201270215A1 (ru) Apaf-1 ингибиторные соединения
EP3747457A3 (de) Faktor-1-protein, faktor-2-protein und inhibitoren davon zur verwendung bei der behandlung und prävention von erkrankungen
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
WO2007098142A3 (en) Oxazole ketones as modulators of fatty acid amide hydrolase
TW200745047A (en) Heterocyclic compounds
WO2004053140A3 (en) Modulators (inhibitors/activators) of histone acetyltransferases
WO2008140708A8 (en) Use of hdac inhibitors for treatment of cardiac rhythm disorders
WO2008070552A3 (en) Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy
WO2008030532A3 (en) Substituted oxazole ketone modulators of fatty acid amide hydrolase
UA97249C2 (ru) Комбинация ингибитора гистоновых дезацетилаз с объединенной активностью относительно гистоновых дезацетилаз класса i и класса ii в с ингибитором протеасом бортезомибом для угнетения роста опухолевых клеток
TN2009000448A1 (en) Use of hdac inhibitors for the treatment of bone destruction
Liu et al. Postoperative pancreatic leakage might improve the survival of patients with carcinoma of head of pancreas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1591109

Country of ref document: EP